Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel

Friday, July 29, 2022

Todos Medical, Ltd., a medical diagnostics company, has announced an agreement between its laboratory, Provista Diagnostics, and Amerimmune Diagnostics, a leader in immune diagnostics. The agreement aims to provide clinically validated immune panels to assess patients with acute and long-COVID.

Provista will measure the production of neutralizing antibodies to the SARS-CoV-2 virus, while Amerimmune will offer insights into inflammatory responses, immune system function, and immune compromise. The testing will help identify patients who may benefit from Evusheld® treatment or other clinical approaches.

Amerimmune has a partnership with Quest Diagnostics for nationwide blood sample collection, which will facilitate access for Long COVID patients interested in getting tested.

The Long COVID Panel includes various markers to monitor immune system cells and biomarkers related to COVID-19. It consists of lymphocyte subsets, T Cell panel, B cell panel, LAG-3, Caspase-1, ICOS, HLA-DR, CD3, CD4, CD45RA, CD45RO, CD38, CD28, CD8, CD45, CXCR5, CD39, CD127, CCR7, CD25, CD317, CD27, CD19, CD20, CD59, CD97, CD14, CD55, cPass SARS-CoV-2 neutralizing antibody test, and nucleocapsid (NP) SARS-CoV-2 IgG antibody test. A key feature of this panel is that it distinguishes between naïve and memory B and T cells. The companies expect to improve the Long COVID Panel over time by adding validated biomarkers and removing inconsequential ones.

Todos Medical also offers Tollovid, a dietary supplement aimed at supporting the immune system. Preliminary research suggests that Tollovid may have an impact on neutralizing antibody levels, but further investigation is needed. Participants in case studies have shown varied responses to Tollovid, indicating the complexity of the immune system in relation to neutralizing antibodies.

The testing platform provided by Amerimmune is considered significant and has become a reflex test for determining eligibility for Evusheld. The company believes that monitoring the immune system's core functions is crucial for managing Long COVID and identifying potential interventions for symptomatic improvements.

Todos Medical believes that 3CL protease inhibition and viral neutralization are essential in eliminating viral persistence in Long COVID. The company sees viral persistence as a core feature of virus-induced Long COVID.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress